Brigatinib / Brigatinib (Brigatinib) price

Brigatinib/Brigatinib (Brigatinib) is a drug that is a targeted therapy drug. For the treatment of patients who are positive for a specific genetic variant called the ALK rearrangement in non-small cell lung cancer (NSCLC).

CurrentlyBrigatinib/Brigatinib has been marketed in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.

The mechanism of action of Brigatinib/Brigatinib is to block the growth and spread of tumor cells by inhibiting the activity of ALK fusion protein. ALK rearrangement is a common genetic variation in lung cancer, which causes the ALK gene to fuse with other genes to form a new fusion protein. This fusion protein promotes tumor cell proliferation and survival, therefore, inhibiting its activity may help inhibit tumor development.

Brigatinib/Brigatinib is approved for the treatment of ALK rearrangement-positive NSCLC patients. It can be used as first-line treatment or in patients who have relapsed or become resistant to other treatments. Brigatinib/Brigatinib has shown significant anti-tumor activity in clinical trials, can prolong progression-free survival and overall survival, and also has a certain therapeutic effect on NSCLC patients with brain metastases.